keyword
MENU ▼
Read by QxMD icon Read
search

HIV-related lymphoma

keyword
https://www.readbyqxmd.com/read/28279031/-clinicpathological-features-and-survival-of-patients-with-aids-related-non-hodgkin-s-lymphoma
#1
K Y Sun, X E Gui, D Deng, Y Xiong, L P Deng, S C Gao, Y X Zhang
Objective: To analyze the clinical characteristics, pathological features and survival of patients with AIDS related non-Hodgkin's lymphoma (ARL) . Methods: The clinical data of 53 ARL cases diagnosed and received care at Zhongnan hospital of Wuhan University were retrospectively studied, and 106 controls were enrolled as control group according to 1∶2 for paired cases and control. SPSS 13.0 package was used for statistical analysis. Kaplan-Meier was applied to assess the survival probability. Results: The mean age of patients with ARL was 43 (11-67) years...
February 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/28226184/cd117-kit-is-a-useful-marker-in-the-diagnosis-of-plasmablastic-plasma-cell-myeloma
#2
Etan Marks, Yang Shi, Yanhua Wang
AIMS: Plasmablastic plasma cell myeloma (PPCM) is a rare morphological presentation of multiple myeloma and can resemble plasmablastic lymphoma (PBL), an HIV related lymphoid neoplasm, morphologically and immunophenotypically. We retrospectively searched for factors that could help differentiate these two entities. METHODS: We used Clinical Looking Glass (CLG), a data mining tool, to identify patients with a diagnosis of either PPCM or PBL with a CD117 test performed...
February 22, 2017: Histopathology
https://www.readbyqxmd.com/read/28207555/human-immunodeficiency-virus-negative-plasmablastic-lymphoma-a-case-report-and-literature-review
#3
Li Lin, Xudong Zhang, Meng Dong, Ling Li, Xinhua Wang, Lei Zhang, Xiaorui Fu, Zhenchang Sun, Jingjing Wu, Zhaoming Li, Yu Chang, Yingjun Wang, Zhiyuan Zhou, Mingzhi Zhang, Qingjiang Chen
RATIONALE: Plasmablastic lymphoma (PBL) is a rare subtype of human immunodeficiency virus (HIV)-related non-Hodgkin's lymphoma that predominantly manifests in the oral cavity. PATIENT CONCERNS: Three cases of HIV-negative PBL were reported. DIAGNOSES: HIV-negative PBL INTERVENTIONS:: The patient had undergone chemotherapy. OUTCOMES: Clinical outcomes were very poor in Cases 1 and 3; Case 2, whose diagnosis suggested no bone marrow involvement, is still alive...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28192480/mtor-activity-in-aids-related-diffuse-large-b-cell-lymphoma
#4
Sara H Browne, Julio A Diaz-Perez, Michael Preziosi, Charles C King, George A Jones, Sonia Jain, Xiaoying Sun, Erin G Reid, Scott VandenBerg, Huan-You Wang
BACKGROUND: Patients infected with HIV have a significantly increased risk of developing non-Hodgkin lymphomas despite the widespread use of HAART. To investigate mTOR pathway activity in acquired immunodeficiency syndrome (AIDS) related diffuse large B-cell lymphoma AR-DLBCL, we used immunohistochemistry to examine the presence of the phosphorylated 70 ribosomal S6 protein-kinase (p70S6K), an extensively studied effector of mTOR Complex 1 (mTORC1) and the phosphorylated phosphatase and tensin homolog (pPTEN), a negative regulator of mTORC1 pathway...
2017: PloS One
https://www.readbyqxmd.com/read/28143881/relapse-of-multicentric-castleman-s-disease-following-rituximab-based-therapy-in-hiv-positive-patients
#5
Alessia Dalla Pria, David Pinato, Jennifer Roe, Kikeri Naresh, Mark Nelson, Mark Bower
Successful treatment of HIV associated multicentric Castleman`s disease (HIV+MCD) with rituximab based approaches has dramatically improved survival and reduced the risk of HHV8-associated lymphoma. Longer term outcomes including relapse rates have not been described and are important to establish the potential role of maintenance therapy. A prospective cohort of 84 patients with biopsy proven HIV+MCD were treated with risk stratified rituximab based therapy. Four patients (5%) died from refractory HIV+MCD and 80 achieved clinical remission...
January 31, 2017: Blood
https://www.readbyqxmd.com/read/28090281/successful-treatment-of-immune-reconstitution-inflammatory-syndrome-related-hemophagocytic-syndrome-in-an-hiv-patient-with-primary-effusion-lymphoma
#6
Markela-P Zorzou, Maria Chini, Athina Lioni, Georgios Tsekes, Thomas Nitsotolis, Ioannis Tierris, Nicolaos Panagiotou, Dimitra Rontogianni, Nicolaos Harhalakis, Marios Lazanas
Although the connection of [secondary hemophagocytic syndrome (sHS)] with HIV has been well documented, optimal treatment regimen is not well established. This is due not only to the rarity of the syndrome, but also to the heterogeneity of the involved population. Most cases are related to opportunistic infections or malignancies in advanced stage, but many cases are also related to seroconversion, in the primary infection setting. Moreover, in the [antiretroviral treatment (ART)] era, rare cases of ART-related sHS have been reported...
November 2, 2016: Hematology Reports
https://www.readbyqxmd.com/read/28059857/risk-for-cancer-among-people-living-with-aids-1997-2012-the-s%C3%A3-o-paulo-aids-cancer-linkage-study
#7
Luana F Tanaka, Maria R D O Latorre, Eliana B Gutierrez, Maria P Curado, Guenter Froeschl, Christian Heumann, Karl-Heinz Herbinger
Previous studies have reported an increased risk for certain types of cancer in the HIV-infected population. The aim of this study was to assess the risk for cancer in people with AIDS (PWA) in comparison with the general population in São Paulo (Brazil), between 1997 and 2012. A population-based registry linkage study was carried out to assess the risk for cancer, using a standardized incidence ratio (SIR) approach. A total of 480 102 person-years, of which 337 941 (70.4%) person-years were men, were included in the analysis...
January 4, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28031174/clinical-characteristics-and-prognostic-factors-of-plasmablastic-lymphoma-patients-analysis-of-135-patients-from-the-lysa-group
#8
E Tchernonog, P Faurie, P Coppo, H Monjanel, A Bonnet, M Algarte Génin, M Mercier, J Dupuis, F Bijou, C Herbaux, A Delmer, B Fabiani, C Besson, S Le Gouill, E Gyan, C Laurent, H Ghesquieres, G Cartron
BACKGROUND: Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of HIV positive patients, is now recognized as a distinct aggressive and rare entity of diffuse large B-cells lymphoma (DLBCL) by the WHO (World Health Organization) classification. Since the original description, others cases have been reported. However, these are largely derived from case reports or small series limiting any definitive conclusions on clinical characteristics and outcome. PATIENTS AND METHODS: The clinical, biological, pathological features and outcome of a cohort including 135 patients with PBL, from LYSA centers in France and Belgium, were reported and analyzed...
December 28, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27965075/diagnostic-value-and-safety-of-stereotactic-biopsy-in-acquired-immune-deficiency-syndrome-patients-with-intracranial-lesions-systematic-review-and-meta-analysis
#9
REVIEW
Jibo Zhang, Xuemeng Liu, Kai Fu, Chengshi Xu, Rui Gong, Li Liu, Tao Guo, Hui Zhou, Xinyu Zhao, Jincao Chen, Jie Zhang
OBJECTIVE: To evaluate the diagnostic value and safety of stereotactic biopsy in acquired immune deficiency syndrome (AIDS) patients with intracranial lesions via meta-analysis. METHODS: Relevant cohort studies were identified through a literature search in PubMed, Embase, and Ovid from 1985 to October 1, 2016. Appropriate studies were identified per search criteria. Systematic review and meta-analysis were used to assess the diagnostic success rate, changed management rate, clinical improvement rate, mortality rate, morbidity rate, hemorrhage rate, hemorrhage in morbidity rate, and final histologic diagnosis results...
February 2017: World Neurosurgery
https://www.readbyqxmd.com/read/27905485/b-and-t-lymphocyte-number-and-function-in-hiv-hiv-lymphoma-patients-treated-with-high-dose-chemotherapy-and-autologous-bone-marrow-transplantation
#10
Diego Bertoli, Alessandro Re, Marco Chiarini, Alessandra Sottini, Federico Serana, Viviana Giustini, Aldo M Roccaro, Chiara Cattaneo, Luigi Caimi, Giuseppe Rossi, Luisa Imberti
Combination of anti-retroviral therapy, high-dose chemotherapy (HCT) and autologous stem cell transplantation (ASCT) has led to an improved survival of HIV(+) non-Hodgkin lymphoma (NHL) patients. We compared T- and B-cell subset recovery and related capability to respond to in-vitro stimulation, as well as T-cell repertoire modifications of HIV(+) and HIV(-) NHL patients undergoing HCT and ASCT as first-line consolidation or salvage treatment, using sequential blood samples obtained before and at 3, 6, 12 and 24 months after ASCT...
December 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27888664/ebv-associated-but-hhv8-unrelated-double-hit-effusion-based-lymphoma
#11
Bo-Jung Chen, David Yen-Ting Chen, Chun-Chi Kuo, Shih-Sung Chuang
Effusion-based lymphoma is a rare and unique type of large B-cell lymphoma presenting in effusion without a mass lesion. It shares many clinicopathological features with primary effusion lymphoma (PEL), but is distinct from PEL by the absence of HHV8 association. Double hit lymphoma (DHL) is an aggressive B-cell lymphoma, defined by concurrent rearrangement of MYC and BCL2 or BCL6. DHL often presents as lymphadenopathy or an extranodal mass, but rarely occurs in effusion. Here we report a 61-year-old male with alcoholic cirrhosis presenting as massive ascites and left pleural effusion...
March 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27882054/risk-of-cancer-among-commercially-insured-hiv-infected-adults-on-antiretroviral-therapy
#12
Jeannette Y Lee, Ishwori Dhakal, Corey Casper, Ariela Noy, Joel M Palefsky, Missak Haigentz, Susan E Krown, Richard F Ambinder, Ronald T Mitsuyasu
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database...
2016: Journal of Cancer Epidemiology
https://www.readbyqxmd.com/read/27870005/hiv-protease-inhibitors-for-the-treatment-of-cancer-repositioning-hiv-protease-inhibitors-while-developing-more-potent-no-hybridized-derivatives
#13
REVIEW
Danijela Maksimovic-Ivanic, Paolo Fagone, James McCubrey, Klaus Bendtzen, Sanja Mijatovic, Ferdinando Nicoletti
The possible use of HIV protease inhibitors (HIV-PI) as new therapeutic option for the treatment of cancer primarily originated from their success in treating HIV-related Kaposi's sarcoma (KS). While these findings were initially attributed to immune reconstitution and better control of oncogenic viral infections, the number of reports on solid tumors, KS, lymphoma, fibrosarcoma, multiple myeloma and prostate cancer suggest other mechanisms for the anti-neoplastic activity of PIs. However, a major drawback for the possible adoption of HIV-PIs in the therapy of cancer relies on their relatively weak anticancer potency and important side effects...
November 21, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27859456/clinical-characteristics-and-survival-outcome-of-primary-effusion-lymphoma-a-review-of-105-patients
#14
Mohamed Abd El-Fattah
Primary effusion lymphoma (PEL) is a rare and an aggressive B-cell non-Hodgkin lymphoma with a distinctive clinicobiological features. As a result of the rarity of this malignancy, the overwhelming majority of data come from a case reports or series. Our study aimed to evaluate the clinical features and the survival outcomes of 105 patients with PEL who diagnosed between 2001 and 2012 from the Surveillance Epidemiology and End Results database 18 of the US National Cancer Institute. The Kaplan-Meier curves were constructed and the multivariate Cox model was built to identify survival prognostic factors...
November 18, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27833967/diagnosing-hiv-associated-cerebral-diseases-the-importance-of-neuropathology-in-understanding-hiv
#15
Ioan Alexandru Diaconu, LaurenŢiu MihăiŢă Stratan, Luciana Nichita, Victoria Aramă, Valentina Ruxandra Moroti Constantinescu, Alexandra Ioana Diaconu, Daniela Adriana Ion
The study aims to compare two aspects concerning the diagnosis of acquired immune deficiency syndrome (AIDS)-associated central nervous system (CNS) pathology (neuroAIDS): clinical diagnoses issued ante mortem with pathology results issued post mortem. The group of 39 human immunodeficiency virus (HIV)-positive patients was created over 23 years and is limited by marked heterogeneity. The enrolled cases were treated at the "Prof. Dr. Matei Bals" National Institute for Infectious Diseases, Bucharest, Romania, deceased due to AIDS-related complications and underwent brain necropsies performed in the Pathology Laboratory at the "Colentina" Clinical Hospital, Bucharest...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27822455/burden-of-cancers-attributable-to-infectious-agents-in-nigeria-2012-2014
#16
Michael Odutola, Elima E Jedy-Agba, Eileen O Dareng, Emmanuel Aja Oga, Festus Igbinoba, Theresa Otu, Emmanuel Ezeome, Ramatu Hassan, Clement A Adebamowo
INTRODUCTION: Infections by certain viruses, bacteria, and parasites have been identified as risk factors for some cancers. In Nigeria, like many other developing countries, infections remain a leading cause of morbidity and mortality. While there are data on the incidence of different cancers in Nigeria, there has been no study of cancers attributable to infections. This study was carried out to determine the burden of cancers attributable to infections using data from two population-based cancer registries (PBCRs) in Nigeria...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27819680/syndecan-1-increases-b-lymphoid-cell-extravasation-in-response-to-hiv-1-tat-via-%C3%AE-v%C3%AE-3-pp60src-pp125fak-pathway
#17
C Urbinati, E Grillo, P Chiodelli, C Tobia, F Caccuri, S Fiorentini, G David, M Rusnati
Syndecan-1 is a heparan sulfate proteoglycan (HSPG) commonly upregulated in AIDS-related B lymphoid malignancies. Tat is the main HIV-1 transactivating factor that has a major role in the pathogenesis of AIDS-related lymphomas (ARL) by engaging heparan sulfate proteoglycans (HSPGs), chemokine receptors and integrins at the lymphoid cell (LC) surface. Here B-lymphoid Namalwa cell clones that do not express or overexpress syndecan-1 (EV-Ncs and SYN-Ncs, respectively) were compared for their responsiveness with Tat: in the absence of syndecan-1, Tat induces a limited EV-Nc migration via C-X-C motif chemokine receptor 4 (CXCR4), G-proteins and Rac...
November 7, 2016: Oncogene
https://www.readbyqxmd.com/read/27755153/combination-antiretroviral-therapy-and-cancer-risk
#18
Álvaro H Borges
PURPOSE OF REVIEW: To review the newest research about the effects of combination antiretroviral therapy (cART) on cancer risk. RECENT FINDINGS: HIV+ persons are at increased risk of cancer. As this risk is higher for malignancies driven by viral and bacterial coinfections, classifying malignancies into infection-related and infection-unrelated has been an emerging trend. Cohorts have detected major reductions in the incidence of Kaposi sarcoma and non-Hodgkin lymphoma (NHL) following cART initiation among immunosuppressed HIV+ persons...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27755151/epstein-barr-virus-associated-lymphomas-in-people-with-hiv
#19
Antonino Carbone, Chiara C Volpi, Ambra V Gualeni, Annunziata Gloghini
PURPOSE OF REVIEW: The present review summarizes the association of the different histotypes of Epstein-Barr virus (EBV)-associated lymphomas with known genetic lesions and/or oncogenic viruses. A more comprehensive understanding of the complex interplay existing between genetic abnormalities of tumor cells and the viral contribution to the development of EBV-associated lymphomas is pivotal for the development of more effective treatments. RECENT FINDINGS: Recent evidence indicates that HIV may contribute to lymphomagenesis by acting directly on B lymphocytes as a critical microenvironmental factor...
January 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/27746042/rituximab-in-lymphoma-and-chronic-lymphocytic-leukaemia-a-practice-guideline
#20
A Prica, F Baldassarre, L K Hicks, K Imrie, T Kouroukis, M Cheung
Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aimed to systematically review and update the literature on rituximab in lymphoma and CLL, and provide evidence-based consensus guidelines for its rational use. Validated methodology from the Cancer Care Ontario Program in Evidence-based Care was used. A comprehensive literature search was completed by a methodologist from the Hematology Disease Site Group of Cancer Care Ontario...
January 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
keyword
keyword
29904
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"